Neutral impactStocks
Aurobindo Pharma's US subsidiary gets US FDA's Official Action Indicated classification
CNBC-TV18 29 min ago·11 Nov 2026, 4:12 pm
The US FDA has classified the inspection of Aurobindo Pharma's step-down subsidiary Lannett Company LLC as OAI after issuing four observations during an August inspection. Aurobindo Pharma said it responded to the observations within the stipulated time and that the regulatory action has no impact on its financials or operations.
Affected stocks
Neutral1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Aurobindo Pharma (AUROPHARMA).
- Category: Stocks.
Why it matters
A routine update for Aurobindo Pharma. Use the price and stock snapshot to gauge how the market is responding.
